EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
4.6.1.18 | Acidosis |
10412952 |
Reversible nephrotoxicity of onconase and effect of lysine pH on renal onconase uptake. |
unassigned |
0 |
4.6.1.18 | Adenocarcinoma |
10810394 |
Enhanced cellular radiation sensitivity of androgen-independent human prostate tumor cells by onconase. |
causal interaction diagnostic usage ongoing research therapeutic application |
2 2 4 1 |
4.6.1.18 | Adenocarcinoma |
11002220 |
Human pancreatic ribonuclease 1: expression and distribution in pancreatic adenocarcinoma. |
causal interaction diagnostic usage ongoing research unassigned |
4 4 4 0 |
4.6.1.18 | Adenocarcinoma |
12626415 |
Glycosylation of human pancreatic ribonuclease: differences between normal and tumor states. |
diagnostic usage ongoing research unassigned |
3 4 0 |
4.6.1.18 | Adenocarcinoma |
19126965 |
Altered glycosylation in tumours focused to cancer diagnosis. |
causal interaction diagnostic usage ongoing research unassigned |
3 4 3 0 |
4.6.1.18 | Adenocarcinoma |
21594308 |
Tamoxifen in patients with advanced pancreatic adenocarcinoma. |
causal interaction diagnostic usage therapeutic application unassigned |
3 4 3 0 |
4.6.1.18 | Adenocarcinoma |
25533084 |
Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt/mTOR pathway in a ROS-dependent manner. |
diagnostic usage ongoing research therapeutic application unassigned |
1 4 4 0 |
4.6.1.18 | Adenocarcinoma |
26405690 |
Human Cancer Antigen Globo H Is a Cell-Surface Ligand for Human Ribonuclease 1. |
diagnostic usage ongoing research unassigned |
3 4 0 |
4.6.1.18 | Adenocarcinoma |
28561015 |
Necl 4 and RNase 5 Are Important Biomarkers for Gastric and Colon Adenocarcinomas. |
causal interaction diagnostic usage ongoing research therapeutic application |
2 2 4 1 |
4.6.1.18 | Adenocarcinoma of Lung |
9735389 |
Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. |
causal interaction ongoing research therapeutic application unassigned |
1 3 1 0 |